Editorial Board
Editors-in-Chief
  • Edward Chu

    Albert Einstein College of Medicine, USA

    Interests: cancer pharmacology and drug development

  • Enrico Mini

    University of Florence Florence, Italy

    Interests: the mechanisms of tumor drug resistance, in particular to antimetabolites and metal-based drugs, cancer pharmacogenomics and pharmacogenetics, and controlled clinical trials in gastrointestinal cancers

  • Kazuo Umezawa

    Aichi Medical University, Japan

    Interests: CPR, resuscitation, critical care medicine, intensive care medicine, hypothermia, emergency management, emergency treatment, sepsis, ventilation, ICU

Editorial Board Members
  • Jinhua Wang

    National Center for Pharmaceutical Screening, Institute of Materia Medica, China

    Interests: the mechanism and drug targets of cancers

  • Makoto Kawatani

    RIKEN Center for Sustainable Resource Science (CSRS), Japan

    Interests: Chemical biology, Drug development and Cancer research

  • Nocentini Giuseppe

    University of Perugia, Italy

    Interests: Pharmacology, Immunotoxicology and Pharmacoimmunology

  • Hiroyuki Osada

    RIKEN Center for Sustainable Resource Science (CSRS), Japan

    Interests: chemical biology research

  • Wunchana Seubwai

    Khon Kaen University, Thailand

    Interests: cancer biology, cell signaling,cell culture, immunohistochemistry, apoptosis, cell proliferation, biochemistry, cancer cell biology, molecular cell biology, gene expression

  • Ryouichi Horie

    Kitasato University, Japan

    Interests: molecular hematology, medical sciences

  • David A. Gewirtz

    Virginia Commonwealth University, USA

    Interests: Autophagy, Cell biology, Programmed cell death, Apoptosis and Senescence

  • Aamir Ahmad

    University of Alabama at Birmingham, USA

    Interests: Cancer Metastasis, Drug Resistance, miRNA and Cancer Health Disparity

  • Isao Momose

    Institute of Microbial Chemistry, Japan

    Interests: Bioorganic chemistry; Applied biochemistry and Applied microbiology

  • Yohko Yamazaki

    Institute of Microbial Chemistry, Japan

    Interests: Androgen receptors, prostate cancer, anticancer drugs and phospholipid remodeling

  • Luca Maria Munaron

    Via Accademia Albertina, Italy.

    Interests: tumor-derivedendothelial cells, drugdelivering against tumor vascularization and Bone vascularization and biomaterials

  • Petar Ozretić

    Laboratory for Hereditary Cancer, Ruđer Bošković Institute (RBI), Croatia

    Interests: Cancer genetics, epigenetics, Bioinformatics, Biostatistics and Molecular oncology

Editorial Advisory Board
  • L. J. Appleman

    University of Pittsburgh, USA

    Interests: tumor immunology, clinical trial of an autologous dendritic cell vaccine, cancer immunotherapy

  • N. Bahary

    University of Pittsburgh, USA

    Interests: oncologists diagnose,cancer surgeons, or surgical oncologists, remove tumors, while medical oncologists treat cancers with chemotherapy, gastrointestinal cancer

  • J. R. Bertino

    Rutgers Cancer Institute of New Jersey, USA

    Interests: cancer biology, lymphomas, antimetabolites

  • J. H. Beumer

    Hillman Cancer Center, USA

    Interests: pharmacology, toxicology

  • M. Boyiadzis

    University of Pittsburgh, USA

    Interests: internal medicine, hematology/oncology, medical oncology

  • Y.-C. Cheng

    Yale University School of Medicine, USA

    Interests: pharmacology, antiviral drugs against HBV, HIV, EBV, and HCV, as well as the discovery of antivirals with unique mode of action against those viruses.

  • M. S. Copur

    University of Nebraska, USA

    Interests: medical oncology, hematology

  • A. Krishnamurthy

    University of Pittsburgh, USA

    Interests: diagnosis and multidisciplinary management of gastrointestinal (GI) cancers

  • Y. Li

    Sorrento Therapeutics, USA

    Interests: tumor immunology, molecular biology, medical genetics and clinical medicine

  • M. Rudek

    Johns Hopkins University, USA

    Interests: clinical pharmacology of anticancer agents; early phase drug development; drug tolerability in cancer patients with HIV/AIDS; drug tolerability in cancer patients with organ dysfunction; blood-brain barrier penetration of drugs.

  • J. C. Schmitz

    University of Pittsburgh, USA

    Interests: pharmacodynamic, the mechanism(s) of action of quassinoids on colorectal cancer cells and tumors

  • N. Wei

    University of Pittsburgh, USA

    Interests: hematology-oncology

  • L. Zhang

    University of Pittsburgh, USA

    Interests: pharmacology and chemical Biology

  • A. H. Calvert

    University of Newcastle upon Tyne, UK

    Interests: tumor biology

  • A. Di Paolo

    University of Pisa, Italy

    Interests: pharmacology, clinical pharmacokinetics and PK/PD of antineoplastic and antiinfective drugs

  • D. Longley

    Queen’s University, UK

    Interests: apoptosis proteins, birinapant, poptosis

  • S. Nobili

    University of Florence, Italy

    Interests: pharmacology, applied pharmacology

  • J. Robert

    Université de Bordeaux, France

    Interests: pharmacocinétique, métabolisme et résistance, pharmacologie cellulaire et moléculaire, pharmacogénétique

  • J. H. M. Schellens

    Netherlands Cancer Institute, the Netherlands

    Interests: clinical pharmacology

  • P. Workman

    CRC Center for Cancer Therapeutics, UK

    Interests: drug discovery, molecular pharmacology and chemical biology approaches

  • A. Deguchi

    Tokyo Women’s Medical University, Japan

    Interests: pharmacology, cancer research

  • X. Ding

    Nanjing Medical University, China

    Interests: digestive diseases

  • S. Gantsev

    Bashkirian State Medical University, Russia

    Interests: pharmacology

  • Y. Horiguchi

    Tokyo Medical University, Japan

    Interests: biomaterials and bioengineering

  • M. Imoto

    Keio University, Japan

    Interests: nanotechnology, materials, chemical biology

  • H. Kakeya

    Kyoto University, Japan

    Interests: chemical biology

  • M. Kawatani

    RIKEN, Japan

    Interests: interdisciplinary science & engineering, biological sciences

  • E. Kikuchi

    Keio University, Japan

    Interests: neuropsychiatry

  • K. P. Kim

    University of Ulsan College of Medicine, Korea

    Interests: pre-medicine, clinical pharmacology

  • T. W. Kim

    University of Ulsan College of Medicine, Korea

    Interests: medicine

  • Y. Lin

    Aichi Medical University, Japan

    Interests: pancreatic cancer, gastric cancer, epidemiologic studies, esophageal cancer

  • J. Neuzil

    Griffith University, Gold Coast Campus, Australia

    Interests: medical microbiology, oncology and carcinogenesis

  • O. Ohno

    Kogakuin University, Japan

    Interests: immunology

  • T. Ohsugi

    Rakuno Gakuen University, Japan

    Interests: genetically modified mice, MNVmouse norovirusspecific pathogen-freemicrobiological monitoringHTLV-1animal modeltaxTransgenic miceATLL

  • M. Oya

    Keio University, Japan

    Interests: urology

  • M. Ozaki

    Hokkaido University, Japan

    Interests: biomedical imaging, oxidative stress, non-alcoholic fatty liver disease

  • Y. Sasazawa

    Juntendo University, Japan

    Interests: proteomics and biomolecular science

  • K. Sidthipong

    Mahidol University, Thailand

    Interests: biology, chemistry, bioorganic & medicinal chemistry letters

  • S. Simizu

    Keio University, Japan

    Interests: cancer, molecular target therapy, inflammation, chemical biology

  • M. Takeiri

    Ivy Cosmetics, Japan

    Interests: osteoclasts

  • E. Tashiro

    Keio University, Japan

    Interests: nature chemical biology

  • T. Ueno

    Tsukuba University, Japan

    Interests: materials science

  • M. Yamamoto

    Waseda University, Japan

    Interests: infrared, FTIR analysis, infrared spectrophotom

Share Link

WeChat scan